AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24423419
Drug: Midazolam (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (initial dose of 0.05 mg/kg, supplemental doses of 0.02 mg/kg)
Trial: 21412134
Drug: Dexamethasone (Dexacort,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (Dexacort, 20 mg)
Trial: 19414694
Drug: DPTaP‐Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPTaP‐Hib vaccine first
Trial: 17846346
Drug: Plasma cardiotrophin-1
RxNorm normalized name: Cardiotrophin 1
DrugBank: Cardiotrophin 1 (DB18399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma cardiotrophin-1 after 1 year of antihypertensive treatment
Trial: 21663809
Drug: Lidocaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (40 mg)
Trial: 10876462
Drug: Propofol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (20 mg)
Trial: 9179056
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chlorambucil (HD-CLB)
Trial: 1489115
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (1 mg/kg over 1 h)
Trial: 2951826
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipratropium bromide (40 micrograms) and fenoterol (200 micrograms)
Trial: 2951826
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipratropium bromide and fenoterol
Trial: 30112792
Drug: MYL-1501D and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MYL-1501D and Insulin glargine
Trial: 21524790
Drug: Cercon control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cercon control (CC)
Trial: 18065202
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone 40 mg once a day for 6 months
Trial: 18065202
Drug: Casein placebo
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein placebo 40 mg once a day for 6 months
Trial: 14556479
Drug: Intensive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive and short duration chemotherapy (LMB protocols)
Trial: 1906239
Drug: TAP-144-SR 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP-144-SR 3.75 mg administered subcutaneously at 4-week intervals for 12 weeks (total of 3 injections)
Trial: 1906239
Drug: Diethylstilbestrol diphosphate
RxNorm normalized name: Diethylstilbestrol Diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol diphosphate 100 mg administered orally three times a day for 12 weeks
Trial: 6125155
Drug: estazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estazolam (2 mg)
Trial: 29238169
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of flupirtine maleate capsule under fasting condition
Trial: 29238169
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of flupirtine maleate capsule under fed condition
Trial: 29238169
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of flupirtine maleate capsule under fasting condition
Trial: 29238169
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of flupirtine maleate capsule under fed condition
Trial: 27798030
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) plus usual care
Trial: 24929624
Drug: sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 100 mg/day
Trial: 22383949
Drug: N-acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-cysteine (NAC) administered for 60 days followed by placebo for another 60 days
Trial: 21158957
Drug: Healthy Foods
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy Foods North (HFN) programme; a multi-institutional and culturally appropriate intervention to improve dietary adequacy and reduce chronic disease risk; specific dosage and duration not available.
Trial: 17685739
Drug: Piracetam (4800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (4800 mg/day)
Trial: 2679938
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (health education promoting a cholesterol-lowering diet, smoking cessation, weight control, physical activity, treatment of arterial hypertension)
Trial: 31248399
Drug: Oral presentation
RxNorm normalized name: Gas-X Prevention Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral presentation
Trial: 30381311
Drug: Tadalafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (20 mg once daily along with conventional management)
Trial: 21275439
Drug: Armodafinil 50
RxNorm normalized name: armodafinil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 50 mg on day 1, 100 mg on day 2, and 150 mg once daily on days 3 through 7
Trial: 19892047
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of autologous mononuclear bone marrow stem cells (BMSCs)
Trial: 11032279
Drug: Traditional antiemetic
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional antiemetic agents (droperidol)
Trial: 11032279
Drug: Traditional antiemetic
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional antiemetic agents (metoclopramide)
Trial: 9064405
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of drugs (group IM)
Trial: 9064405
Drug: Multiple drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple drugs (60%)
Trial: 1338319
Drug: D-F 15
RxNorm normalized name: Mite D.F.
DrugBank: Dermatophagoides farinae (DB10400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-F 15 mg b.d. for 26 weeks
Trial: 8805113
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg acetaminophen
Trial: 11510914
Drug: Standardized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized medical treatment
Trial: 26794722
Drug: Invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive strategy (early coronary angiography with immediate assessment for percutaneous coronary intervention, coronary artery bypass graft, and optimum medical treatment)
Trial: 26794722
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy (optimum medical treatment alone)
Trial: 24886352
Drug: Weekly 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly 1.5 hour weight management group until 6 weeks postpartum, combining Slimming World expertise with NHS midwives' clinical advice.
Trial: 23181339
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration (WBV) intervention, conducted in a home-based setting, for six weeks, twice a week.
Trial: 23181339
Drug: Placebo training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo training intervention, conducted in a home-based setting, for six weeks, after a two-week washout period, twice a week.
Trial: 20103032
Drug: Energy drink
RxNorm normalized name: Boost Energy Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy drink (250 mL, sugar-free)
Trial: 17669707
Drug: Ultrasound-guided fine-needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided fine-needle aspiration (FNA) with measurement of parathyroid hormone (PTH) in the aspirate
Trial: 10457875
Drug: Tramadol drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol drops 1.5 mg kg-1 (n = 31)
Trial: 10432161
Drug: 72-hour intravenous
RxNorm normalized name: 72 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72-hour intravenous tubing set changes
Trial: 10432161
Drug: 24-hour intravenous
RxNorm normalized name: 24 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour intravenous tubing set changes
Trial: 330480
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg amoxycillin three times daily
Trial: 330480
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pivmecillinam three times daily
Trial: 330480
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pivmecillinam three times daily
Trial: 28257752
Drug: Idelalisib plus
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib plus ofatumumab (oral idelalisib 150 mg twice daily continuously plus ofatumumab 300 mg intravenously in week 1, then 1000 mg intravenously weekly for 7 weeks, and every 4 weeks for 16 weeks)
Trial: 28257752
Drug: Ofatumumab alone
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab alone (ofatumumab dosing as per the combination group, except 2000 mg was substituted for the 1000 mg dose)
Trial: 25981401
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no tadalafil treatment)
Trial: 19253237
Drug: Tafluprost 0.0015%
RxNorm normalized name: TAFLUPROST 0.0015% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafluprost 0.0015% (once daily) with timolol 0.5% (twice daily)
Trial: 19253237
Drug: Vehicle with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle with timolol 0.5% (twice daily)
Trial: 9468460
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CsA; 10 mg/kg)
Trial: 8560834
Drug: Indobufen 400
RxNorm normalized name: indobufen
DrugBank: Indobufen (DB12545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen 400 mg perorally, given one day prior to operation and continued daily for three months
Trial: 8560834
Drug: Indobufen treatment
RxNorm normalized name: indobufen
DrugBank: Indobufen (DB12545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen treatment
Trial: 2884190
Drug: Mifentidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifentidine (10 mg)
Trial: 26718605
Drug: IV delafloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV delafloxacin (300 mg)
Trial: 26718605
Drug: Oral delafloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral delafloxacin (450 mg)
Trial: 15960642
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 0.75 ml.kg(‐1)
Trial: 15960642
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 0.75 ml.kg(‐1) plus clonidine 1 microg.kg(‐1)
Trial: 15960642
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 0.75 ml.kg(‐1) plus ketamine 0.5 mg.kg(‐1)
Trial: 10348223
Drug: Malarone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malarone (250 mg of atovaquone/100 mg of proguanil hydrochloride per tablet)
Trial: 7491835
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta‐estradiol matrix patch (0.05 mg/day)
Trial: 9573748
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (0.625 mg/day)
Trial: 7491835
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta‐estradiol matrix patch
Trial: 9467549
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens
Trial: 161858
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing 0.05 mg of ethinylestradiol and 0.100 mg or 0.125 mg of a new progestogen (17 alpha‐ethinyl‐18‐methylene‐4‐estren‐17 beta‐ol)
Trial: 31172416
Drug: pegylated-interferon (peg-IFN)
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated-interferon (peg-IFN) consolidation treatment for 48 weeks
Trial: 31172416
Drug: nucleos(t)ide analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nucleos(t)ide analogue (NA) consolidation treatment for 48 weeks
Trial: 29962050
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg every month (QM)
Trial: 26862823
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention (8 weekly sessions)
Trial: 16403233
Drug: Intravenous cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cimetidine 800 mg per day
Trial: 16403233
Drug: Oral omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral omeprazole 40 mg per day
Trial: 8499355
Drug: Both twins
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both twins on identical tapering regimen of corticosteroids over 3 months
Trial: 3318799
Drug: Scopolamine 0.6
RxNorm normalized name: scopolamine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.6 mg with d-amphetamine 5 mg
Trial: 3318799
Drug: Scopolamine 0.6
RxNorm normalized name: scopolamine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.6 mg with d-amphetamine 5 mg and neostigmine 15 mg
Trial: 3318799
Drug: Neostigmine 15
RxNorm normalized name: neostigmine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 15 mg
Trial: 31617447
Drug: Mastery Learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastery Learning (ML)
Trial: 15963119
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist treatment for 3-5 months before radical radiotherapy
Trial: 11393207
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate cream (Temovate®) applied twice daily for 3 or 4 weeks
Trial: 9278462
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (tinzaparin)
Trial: 3501728
Drug: Ro 15-8081
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-8081 (10 mg)
Trial: 3501728
Drug: Ro 15-8081
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-8081 (25 mg)
Trial: 3501728
Drug: Ro 15-8081
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-8081 (50 mg)
Trial: 10896014
Drug: Codeine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (60 mg)
Trial: 29753374
Drug: Pentoxifylline 400mg
RxNorm normalized name: PENTOXIFYLLINE 400MG TAB,SA
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400mg b.i.d. plus losartan 50mg daily
Trial: 27124177
Drug: Guided neoadjuvant
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided neoadjuvant chemotherapy (guided‐NACT)
Trial: 27124177
Drug: Conventional neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional neoadjuvant chemotherapy (conventional‐NACT)
Trial: 26404395
Drug: Levosulpiride 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride 50 mg tablets, 3 times daily
Trial: 26404395
Drug: Levosulpiride 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride 50 mg injection (IM), twice daily
Trial: 21360537
Drug: Subareolar injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subareolar injection of methylene blue (MB)
Trial: 21360537
Drug: Peritumoral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritumoral injection of methylene blue (MB)
Trial: 27737664
Drug: etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 60 mg
Trial: 27737664
Drug: etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 90 mg
Trial: 17184507
Drug: [(13)C]‐acetate breath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(13)C]‐acetate breath test (ABT) with 100 mg [(13)C]‐acetate and 200 kcal liquid meal
Trial: 17184507
Drug: High viscosity
RxNorm normalized name: Mineral Oil, High Viscosity
DrugBank: Light mineral oil (DB11579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High viscosity meal (gel-forming agent added)
Trial: 1484192
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine (CRM) suspension (SAR 213)
Trial: 1484192
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine (CRM) tablets (Moscontin)
Trial: 24947950
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic antibiotics
Trial: 27885425
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) - single injection 4 µg/kg before skin incision (n = 23)
Trial: 27885425
Drug: Intravenous opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous opioids (IVO) - iv remifentanil infusion during surgery followed by i.v. bolus of morphine, 0.15 mg/kg before the end of surgery (n = 26)
Trial: 21299684
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block with 0.7 ml·kg(‐1) of 1.0% lidocaine containing epinephrine at 5 μg·ml(‐1)
Trial: 11758229
Drug: M group
RxNorm normalized name: malarial plasmodium group immunoserum rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M group and L group (moderate and major renal dysfunction)
Trial: 9218948
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg orally every 8 h for 10 days
Trial: 3307487
Drug: 0.7 ml
RxNorm normalized name: ethanol 0.7 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 ml of Alcohol per kg body weight
Trial: 3307487
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of Alcohol per kg body weight
Trial: 23150720
Drug: Triple-drug chemolipiodolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug chemolipiodolization with sponge embolization (Arm 1)
Trial: 23150720
Drug: Triple-drug chemolipiodolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug chemolipiodolization without embolization (Arm 2)
Trial: 23150720
Drug: Single-drug chemolipiodolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-drug chemolipiodolization with sponge embolization (Arm 3)
Trial: 2507875
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (n = 6) - saline injections
Trial: 16806
Drug: Liquid Maalox,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid Maalox, 30 ml, 1 and 3 hr after a meal
Trial: 31616932
Drug: Avocado diet
RxNorm normalized name: Avocado
DrugBank: Avocado (DB10504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avocado diet (1 Hass avocado, ∼136 g per day)
Trial: 24488582
Drug: lynestrenol (LYN)
RxNorm normalized name: lynestrenol
DrugBank: Lynestrenol (DB12474)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lynestrenol (LYN) 15 mg/d
Trial: 24488582
Drug: micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: micronized progesterone (MP) 200 mg/d
Trial: 20804358
Drug: Therapy tapering
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy tapering (occlusion reduced from full-time to 50% of waking hours, then to 25%, and discontinued at week 8)
Trial: 20804358
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (abrupt cessation and therapy tapering)
Trial: 29532635
Drug: Broccoli sprouts
RxNorm normalized name: broccoli sprout extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli sprouts incorporated in gels (protein, fiber, lipid)